ACRS on Nasdaq
Aclaris Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Pulmatrix, Inc., Cogent Biosciences, Inc. or Coya Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-975.9%Operating margin3
-829.6%Net margin3
-58.2%Revenue growth, 20253
-63.0%Return on equity3
-$47.2MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License and Service brought in 76% of the revenue Aclaris Therapeutics, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| License and Service | $16.2M | $6.0M |
| Contract research | $2.5M | $1.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue4¢$2.1M
- Research and development96¢$52.6M
Out of $7.8M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $7.8M | $18.7M |
| Cost of revenue | $2.1M | $2.8M |
| Research and development | $52.6M | $33.6M |
| General and administrative | $22.0M | $22.2M |
| Licensing | $5.2M | $12.7M |
| Revaluation of contingent consideration | $2.3M | $2.5M |
| In-process research and development | $86.9M | |
| Total costs and expenses | $84.2M | $160.7M |
| Loss from operations | -$76.4M | -$141.9M |
| Interest income | $7.6M | $8.0M |
| Non-cash royalty income | $3.8M | $1.9M |
| Total other income | $11.5M | $9.9M |
| Net loss | -$64.9M | -$132.1M |
| Net loss per share, basic | -$0.53 | -$1.71 |
| Net loss per share, diluted | -$0.53 | -$1.71 |
| Weighted average common shares outstanding, basic | 122.6M shares | 77.3M shares |
| Weighted average common shares outstanding, diluted | 122.6M shares | 77.3M shares |
| Unrealized gain on marketable securities, net of tax of $0 | $513.0K | $203.0K |
| Total other comprehensive income | $513.0K | $203.0K |
| Comprehensive loss | -$64.4M | -$131.9M |
| Unrealized gain on marketable securities, tax | $0 | $0 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-05-31 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $20.0M | $24.6M | |
| Short-term marketable securities | $70.8M | $89.0M | |
| Accounts receivable, prepaid expenses and other current assets | $5.6M | $12.4M | |
| Total current assets | $96.3M | $126.0M | |
| Marketable securities | $60.6M | $90.3M | |
| Property and equipment, net | $761.0K | $1.0M | |
| Other assets | $2.8M | $3.1M | |
| Total assets | $160.5M | $220.3M | |
| Accounts payable | $13.2M | $4.7M | |
| Accrued expenses | $8.8M | $20.3M | |
| Deferred income | $3.9M | $3.9M | |
| Other current liabilities | $2.8M | $2.7M | |
| Total current liabilities | $28.6M | $31.6M | |
| Other liabilities | $1.6M | $4.4M | |
| Deferred income, net of current portion | $16.2M | $20.0M | |
| Contingent consideration | $11.0M | $8.7M | |
| Total liabilities | $57.4M | $64.8M | |
| Common stock, $0.00001 par value; 400,000,000 and 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 120,499,433 and 107,850,124 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $1.0K | $1.0K | |
| Additional paidin capital | $1.1B | $1.1B | |
| Accumulated other comprehensive income | $610.0K | $97.0K | |
| Accumulated deficit | -$967.8M | -$902.9M | |
| Total stockholders' equity | $103.1M | $155.6M | |
| Total liabilities and stockholders' equity | $160.5M | $220.3M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 400.0M shares | 200.0M shares | 200.0M shares |
| Common stock, shares issued (in shares) | 120.5M shares | 107.9M shares | |
| Common stock, shares outstanding (in shares) | 120.5M shares | 107.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$64.9M | -$132.1M |
| Depreciation and amortization | $454.0K | $807.0K |
| Stock-based compensation expense | $12.4M | $10.9M |
| Revaluation of contingent consideration | $2.3M | $2.5M |
| In-process research and development expense | $86.9M | |
| Accounts receivable, prepaid expenses and other assets | $6.1M | -$4.9M |
| Accounts payable | $8.4M | -$4.2M |
| Accrued expenses and other liabilities | -$8.1M | -$3.9M |
| Deferred income | -$3.8M | $23.9M |
| Net cash used in operating activities | -$47.1M | -$20.1M |
| Purchases of property and equipment | -$111.0K | -$121.0K |
| Purchases of marketable securities | -$39.7M | -$120.0M |
| Proceeds from sales and maturities of marketable securities | $89.0M | $86.1M |
| Payments of deferred transaction consideration for in-licensed assets | -$833.0K | |
| Acquisition of in-licensed assets, including transaction costs | -$35.8M | |
| Net cash provided by (used in) investing activities | $48.4M | -$69.8M |
| Proceeds from issuance of common stock under securities purchase agreement, net of issuance costs | $74.9M | |
| Payments of deferred transaction consideration for in-licensed assets | -$5.4M | |
| Payments of employee withholding taxes related to restricted stock unit award vesting | -$446.0K | -$409.0K |
| Proceeds from exercise of employee stock options and the issuance of stock | $32.0K | |
| Net cash (used in) provided by financing activities | -$5.9M | $74.5M |
| Net decrease in cash and cash equivalents | -$4.6M | -$15.3M |
| Additions to property and equipment included in accounts payable | $21.0K | |
| Fair value of warrants issued in connection with in-license agreement | $44.8M | |
| Deferred transaction consideration in connection with in-license agreement | $6.2M |
Recent filings
- Sep 21, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Aug 6, 2026S-3ASR
- Aug 6, 20268-K
- Aug 4, 20264
- Jun 8, 20264
- Jun 8, 20264
- Jun 8, 20264
- Jun 8, 20264
- Jun 8, 20264
- Jun 8, 20264
- Jun 4, 20268-K
- May 12, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10